NEW YORK, Nov. 14, 2017 /PRNewswire/ -- If you want a Stock Review on OPHT, PTCT, TRVN, or TSRO then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. Today's research on DailyStockTracker.com is dedicated to the Biotech sector, which harnesses biological processes to create technologies and products for a wide variety of challenges - from expanding crop sizes to treating disease. Equities under assessment this morning are: Ophthotech Corp. (NASDAQ: OPHT), PTC Therapeutics Inc. (NASDAQ: PTCT), Trevena, Inc. (NASDAQ: TRVN), and Tesaro Inc. (NASDAQ: TSRO). Register now and get full and free access to these DailyStockTracker.com research reports at:
http://dailystocktracker.com/register/
Ophthotech
On Monday, shares in New York headquartered Ophthotech Corp. recorded a trading volume of 2.81 million shares, which was above their three months average volume of 612,910 shares. The stock ended at $3.20, jumping 11.89% from the last trading session. The Company's shares have gained 21.67% in the last one month and 17.65% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 23.40% and 7.96%, respectively. Furthermore, shares of Ophthotech, which develops novel therapeutics to treat diseases of the back of the eye, have a Relative Strength Index (RSI) of 80.14.
On November 08th, 2017, Ophthotech announced financial and operating results for Q3 ended September 30th, 2017. Collaboration revenue was $206.7 million for the quarter; R&D expenses were $10.7 million; G&A expenses were $7.1 million; and net income was $189.1 million. As of September 30th, 2017, the Company had $180.2 million in cash and cash equivalents. Access our complete research report on OPHT for free at:
http://dailystocktracker.com/registration/?symbol=OPHT
PTC Therapeutics
New Jersey headquartered PTC Therapeutics Inc.'s stock finished yesterday's session 3.24% lower at $15.53 with a total trading volume of 1.13 million shares. The Company's shares have surged 42.35% on an YTD basis. The stock is trading slightly below its 200-day moving average by 0.16%. Furthermore, shares of PTC Therapeutics, which focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes, have an RSI of 37.16.
On October 25th, 2017, PTC Therapeutics announced that the Office of Drug Evaluation I of the US FDA has issued a complete response letter for the New Drug Application of the investigational medicine ataluren for the treatment of nonsense mutation dystrophinopathies. The letter indicated that evidence of effectiveness from an additional adequate and well-controlled clinical trial(s) will be necessary at a minimum to provide substantial evidence of effectiveness.
On October 26th, 2017, research firm Bank of America/ Merrill downgraded the Company's stock rating from 'Neutral' to 'Underperform'. The complimentary research report on PTCT can be downloaded at:
http://dailystocktracker.com/registration/?symbol=PTCT
Trevena
At the close of trading on Monday, shares in Pennsylvania headquartered Trevena, Inc. saw a drop of 11.80%, ending the day at $1.57. The stock recorded a trading volume of 1.28 million shares, which was above its three months average volume of 685,330 shares. The Company's shares are trading 26.41% below their 50-day moving average. Moreover, shares of Trevena have an RSI of 41.42.
On October 25th, 2017, Trevena announced that it presented two posters describing the results of APOLLO-1 and APOLLO-2 - the Company's two successful Phase 3 pivotal efficacy studies of OLINVO - at the 2017 Annual Meeting of the American Society of Anesthesiologists held last October 21st, 2017, to October 25th, 2017 in Boston. The Company also announced that results of its Phase 2b trial of Breakthrough Therapy-designated OLINVO (oliceridine injection) have been published in the peer-reviewed Journal of Pain Research.
On November 08th, 2017, research firm Needham reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $9 a share to $7 a share. Register for free on DailyStockTracker.com and get access to the latest report on TRVN at:
http://dailystocktracker.com/registration/?symbol=TRVN
Tesaro
Waltham, Massachusetts headquartered Tesaro Inc.'s shares ended the day 0.70% lower at $90.45. A total volume of 1.05 million shares was traded, which was above their three months average volume of 859,360 shares. The stock is trading 22.90% below its 50-day moving average. Additionally, shares of Tesaro, which identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the US, have an RSI of 22.19.
On October 23rd, 2017, research firm Piper Jaffray resumed its 'Neutral' rating on the Company's stock, with a target price of $117 per share.
On October 23rd, 2017, Tesaro announced that Lonnie Moulder, CEO, and Mary Lynne Hedley, Ph.D., President and COO, are scheduled to participate in an analyst-led fireside chat at The Evercore ISI BioPharma Catalyst/Deep Dive Conference on November 29th, 2017, from 3:50 p.m. to 4:35 p.m. ET at the Boston Harbor Hotel in Boston. A live webcast of the presentation will be available under the Investors section of the Company's website. The free report on TSRO can be downloaded at:
http://dailystocktracker.com/registration/?symbol=TSRO
--
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://dailystocktracker.com/disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: [email protected] Phone number: (207)331-3313Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Advertisement
http://dailystocktracker.com/register/
Ophthotech
On Monday, shares in New York headquartered Ophthotech Corp. recorded a trading volume of 2.81 million shares, which was above their three months average volume of 612,910 shares. The stock ended at $3.20, jumping 11.89% from the last trading session. The Company's shares have gained 21.67% in the last one month and 17.65% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 23.40% and 7.96%, respectively. Furthermore, shares of Ophthotech, which develops novel therapeutics to treat diseases of the back of the eye, have a Relative Strength Index (RSI) of 80.14.
Advertisement
On November 08th, 2017, Ophthotech announced financial and operating results for Q3 ended September 30th, 2017. Collaboration revenue was $206.7 million for the quarter; R&D expenses were $10.7 million; G&A expenses were $7.1 million; and net income was $189.1 million. As of September 30th, 2017, the Company had $180.2 million in cash and cash equivalents. Access our complete research report on OPHT for free at:
http://dailystocktracker.com/registration/?symbol=OPHT
PTC Therapeutics
New Jersey headquartered PTC Therapeutics Inc.'s stock finished yesterday's session 3.24% lower at $15.53 with a total trading volume of 1.13 million shares. The Company's shares have surged 42.35% on an YTD basis. The stock is trading slightly below its 200-day moving average by 0.16%. Furthermore, shares of PTC Therapeutics, which focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes, have an RSI of 37.16.
On October 25th, 2017, PTC Therapeutics announced that the Office of Drug Evaluation I of the US FDA has issued a complete response letter for the New Drug Application of the investigational medicine ataluren for the treatment of nonsense mutation dystrophinopathies. The letter indicated that evidence of effectiveness from an additional adequate and well-controlled clinical trial(s) will be necessary at a minimum to provide substantial evidence of effectiveness.
On October 26th, 2017, research firm Bank of America/ Merrill downgraded the Company's stock rating from 'Neutral' to 'Underperform'. The complimentary research report on PTCT can be downloaded at:
http://dailystocktracker.com/registration/?symbol=PTCT
Trevena
At the close of trading on Monday, shares in Pennsylvania headquartered Trevena, Inc. saw a drop of 11.80%, ending the day at $1.57. The stock recorded a trading volume of 1.28 million shares, which was above its three months average volume of 685,330 shares. The Company's shares are trading 26.41% below their 50-day moving average. Moreover, shares of Trevena have an RSI of 41.42.
On October 25th, 2017, Trevena announced that it presented two posters describing the results of APOLLO-1 and APOLLO-2 - the Company's two successful Phase 3 pivotal efficacy studies of OLINVO - at the 2017 Annual Meeting of the American Society of Anesthesiologists held last October 21st, 2017, to October 25th, 2017 in Boston. The Company also announced that results of its Phase 2b trial of Breakthrough Therapy-designated OLINVO (oliceridine injection) have been published in the peer-reviewed Journal of Pain Research.
On November 08th, 2017, research firm Needham reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $9 a share to $7 a share. Register for free on DailyStockTracker.com and get access to the latest report on TRVN at:
http://dailystocktracker.com/registration/?symbol=TRVN
Tesaro
Waltham, Massachusetts headquartered Tesaro Inc.'s shares ended the day 0.70% lower at $90.45. A total volume of 1.05 million shares was traded, which was above their three months average volume of 859,360 shares. The stock is trading 22.90% below its 50-day moving average. Additionally, shares of Tesaro, which identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the US, have an RSI of 22.19.
On October 23rd, 2017, research firm Piper Jaffray resumed its 'Neutral' rating on the Company's stock, with a target price of $117 per share.
On October 23rd, 2017, Tesaro announced that Lonnie Moulder, CEO, and Mary Lynne Hedley, Ph.D., President and COO, are scheduled to participate in an analyst-led fireside chat at The Evercore ISI BioPharma Catalyst/Deep Dive Conference on November 29th, 2017, from 3:50 p.m. to 4:35 p.m. ET at the Boston Harbor Hotel in Boston. A live webcast of the presentation will be available under the Investors section of the Company's website. The free report on TSRO can be downloaded at:
http://dailystocktracker.com/registration/?symbol=TSRO
--
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://dailystocktracker.com/disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: [email protected] Phone number: (207)331-3313Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/daily-technical-summary-reports-on-biotech-stocks----ophthotech-ptc-therapeutics-trevena-and-tesaro-300555400.html
SOURCE dailystocktracker.com
